Breaking News Instant updates and real-time market news.

CCI

Crown Castle

$120.17

(0.00%)

, NEE

NextEra Energy

$185.39

(0.00%)

09:40
02/20/19
02/20
09:40
02/20/19
09:40

Unusually active option classes on open February 20th

Unusual total active option classes on open include: Crown Castle (CCI), NextEra Energy (NEE), Devon Energy (DVN), CVS Health (CVS), Elanco Animal Health (ELAN), Freeport McMoRan (FCX), Bausch Health (BHC), Wal-Mart (WMT), Adobe (ADBE), and Ford (F).

CCI

Crown Castle

$120.17

(0.00%)

NEE

NextEra Energy

$185.39

(0.00%)

DVN

Devon Energy

$28.31

(0.00%)

CVS

CVS Health

$69.92

(0.00%)

ELAN

Elanco

$29.18

(0.00%)

FCX

Freeport McMoRan

$13.09

(0.00%)

BHC

Bausch Health

$25.17

(0.00%)

WMT

Walmart

$102.23

(0.00%)

ADBE

Adobe

$257.84

(0.00%)

F

Ford

$8.83

(0.00%)

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 23

    Oct

CCI Crown Castle
$120.17

(0.00%)

02/12/19
MACQ
02/12/19
DOWNGRADE
MACQ
Neutral
Crown Castle downgraded to Neutral from Outperform at Macquarie
12/12/18
WELS
12/12/18
NO CHANGE
Target $129
WELS
Outperform
Crown Castle price target raised to $129 from $123 at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche raised her price target for Crown Castle to $129 from $123 after traveling with management. The analyst walked away from these meetings with increased conviction in the company's strategy and drivers of growth. Crown Castle is Fritzsche's top tower pick for 2019. She reiterates an Outperform rating on the shares.
12/12/18
12/12/18
DOWNGRADE
Target $170

Equal Weight
American Tower downgraded to Equal Weight after outperformance at Morgan Stanley
As previously reported, Morgan Stanley analyst Simon Flannery downgraded American Tower (AMT) to Equal Weight from Overweight, citing the stock's strong relative performance in 2018 compared to peers. While he remains supportive of the Tower companies overall, Flannery believes American Tower has a slightly more difficult set-up with strong domestic growth more priced in. He maintains a $170 price target on the shares. Flannery keeps Overweight ratings on SBA Communications (SBAC) and Crown Castle (CCI), stating that the Towers as a group have the best business model in his combined Telecom coverage due to their strong operating fundamentals, high barriers to entry and unique competitive characteristics.
01/14/19
GSCO
01/14/19
DOWNGRADE
Target $110
GSCO
Neutral
Crown Castle downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Brett Feldman downgraded Crown Castle (CCI) to Neutral and lowered his price target for the shares to $110 from $116. The analyst believes tower stocks are appropriately priced given his expectations for growth in 2019. "Near-peak growth expectations" are priced in at current share levels, Feldman tells investors in a research note. The analyst also laid his top picks in Americas Telecom Services. His favorite defensive stock is Verizon (VZ), his favorite value stock is Altice USA (ATUS), his most catalyst driven idea is Zayo Group (ZAYO) and his top data center operator is Equinix (EQIX).
NEE NextEra Energy
$185.39

(0.00%)

09/21/18
09/21/18
NO CHANGE

Morgan Stanley shakes up utility ratings, upgrades Atmos, downgrades Xcel
As previously reported, Morgan Stanley analyst Stephen Byrd upgraded Atmos Energy (ATO) to Overweight from Equal Weight as he laid out his favorite ideas in regulated utilities based on his estimates of their 2020 earnings power. Byrd believes Atmos' 5% discount to the gas utility group undervalues its "best-in-class" growth outlook and attractive regulatory environment, he tells investors. Byrd also downgraded Xcel Energy (XEL) to Equal Weight from Overweight, telling investors that he sees modest level of upside remaining in the stock and few near-term catalysts for outperformance. In shifting his focus to 2020 earnings power, Byrd also identifies FirstEnergy (FE), PSEG (PEG), American Electric (AEP) and NextEra Energy (NEE) as stocks in the group with undervalued growth.
12/12/18
FBCO
12/12/18
NO CHANGE
Target $193
FBCO
Outperform
NextEra Energy price target raised to $193 from $186 at Credit Suisse
Credit Suisse analyst Michael Weinstein raised his price target for NextEra to $193 from $186 to reflect higher peer group average 2020 P/Es. The analyst reiterates an Outperform rating on the shares as he expects a disciplined approach to M&A to continue.
11/01/18
RBCM
11/01/18
NO CHANGE
Target $186
RBCM
Outperform
NextEra Energy price target raised to $186 from $173 at RBC Capital
RBC Capital analyst Shelby Tucker raised his price target on NextEra Energy to $186 and kept his Outperform rating after its Q3 earnings beat last week. The analyst says the stock should be a "core holding within a broader portfolio, let alone in a utility fund". Tucker notes that his new price target mostly reflects the impact of the acquisition of Gulf Power but also anticipates its earnings growth of 8%-10% and dividend growth of over 12% for the "foreseeable future".
10/10/18
WELS
10/10/18
NO CHANGE
Target $200
WELS
Outperform
NextEra Energy price target raised to $200 from $191 at Wells Fargo
Wells Fargo analyst Neil Kalton raised his price target for NextEra Energy to $200 from $191 after meeting with management. The analyst does not think shares adequately reflect the likely sustainability of NextEra's 8%-plus EPS CAGR well beyond the company's 2018-2021 forecast period. Kalton believes renewables growth should continue to surprise to the upside and NextEra should be able to execute on a series of accretive regulated utility company and/or asset acquisitions over the next decade to supplement the already strong growth at FPL. He reiterates an Outperform rating on the stock.
DVN Devon Energy
$28.31

(0.00%)

01/16/19
LEHM
01/16/19
NO CHANGE
LEHM
Barclays upgrades Concho, downgrades Devon, Centennial and Callon
Barclays analyst Jeanine Wai upgraded Concho Resources (CXO) to Overweight from Equal Weight while downgrading both Devon Energy (DVN) and Callon Petroleum (CPE) to Equal Weight from Overweight and double downgrading Centennial Resource Development (CDEV) to Underweight from Overweight. Sustainable free cash flow with growth continues to be the "holy grail" in Exploration and Production, Wai tells investors in a research note. In 2019 the analyst thinks there will be a "distinct bifurcation" among stocks and the "line in the sand" is sustainable free cash flow yield plus growth. Barring a more imminent oil price recovery, Centennial Resource will likely underperform as valuation climbs due to continued cash burn and decelerating cash flow growth, says the analyst. Further, despite carrying some momentum, Callon's valuation screens rich "given less visibility on its journey" to positive free cash flow, adds Wai.
01/16/19
LEHM
01/16/19
DOWNGRADE
Target $33
LEHM
Equal Weight
Devon Energy downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Jeanine Wai downgraded Devon Energy to Equal Weight and lowered her price target for the shares to $33 from $42.
01/08/19
JRCO
01/08/19
DOWNGRADE
JRCO
Accumulate
Devon Energy downgraded to Accumulate from Buy at Johnson Rice
12/21/18
SOCO
12/21/18
UPGRADE
Target $20
SOCO
Equalweight
Devon Energy upgraded to Equalweight from Underweight at Capital One
Capital One upgraded Devon Energy to Equalweight from Underweight a day after downgraded the stock to Underweight. Capital One said its weighted average oil price realization calculation was busted, which artificially skewed realizations. As a result, the firm corrected its mistake by adding back free cash flow for 2019/20.
CVS CVS Health
$69.92

(0.00%)

02/20/19
WELS
02/20/19
DOWNGRADE
WELS
Market Perform
CVS Health downgraded to Market Perform from Outperform at Wells Fargo
02/07/19
MSCO
02/07/19
NO CHANGE
Target $100
MSCO
Overweight
CVS shares could rise 4%-9% on 'good enough' guidance, says Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser noted that CVS Health will provide guidance on February 20 for the first time since completing the Aetna transaction and he puts 60% odds on initial FY19 EPS guidance of $7.00-$7.30. While such an outlook would be below the current consensus of $7.44, bears are concerned guidance could be below $7 and such an outlook would be seen as "good enough" to drive the stock up 4%-9%, Goldwasser tells investors. If initial 2019 EPS guidance is below $7.00, which is a scenario he gives a 30% probability, the stock could be down 11%. If the initial 2019 EPS guidance range has a midpoint above $7.40, which Goldwasser assigns only 10% odds of happening, the stock could be up 10%, the analyst said. He keeps an Overweight rating and $100 price target on CVS shares ahead of the company's December quarter earnings report.
02/20/19
WELS
02/20/19
DOWNGRADE
Target $68
WELS
Market Perform
Wells Fargo downgrades CVS Health to Market Perform, slashes price target to $68
As previously reported, Wells Fargo analyst Peter Costa downgraded CVS Health to Market Perform from Outperform based on its "continued failure" to stabilize its existing businesses, particularly the long-term care business, after two years of pressure. Beyond the "obvious need" to integrate the Aetna acquisition, CVS expects the ongoing business pressures to have an outsized impact on 2019, making it a transition year, said Costa, who called the company's 2019 adjusted EPS guidance of $6.68-$6.88 "disappointing." He lowered his 2019 EPS estimate to $6.78 and cut his price target on CVS Health shares to $68 from $104.
01/31/19
MSCO
01/31/19
NO CHANGE
Target $391
MSCO
Overweight
Anthem price target raised to $391 from $372 at Morgan Stanley
Morgan Stanley analyst Zack Sopcak said Anthem's (ANTM) launch of IngenioRx three quarters early, giving it a presence in the 2020 selling season, leads him to see an increased likelihood of gaining share as compared to entry in the 2021 selling season when CVS Health (CVS) and Cigna (CI) would have more time for their marketing messages to mature post their respective mergers. While also noting that Anthem's 2019 guidance for EPS of $19+ came in well above estimates, Sopcak raised his price target on the stock to $391 from $372 and reiterated as a top pick with an Overweight rating.
ELAN Elanco
$29.18

(0.00%)

02/11/19
WBLR
02/11/19
INITIATION
WBLR
Market Perform
Elanco initiated with a Market Perform at William Blair
William Blair analyst John Kreger started Elanco Animal Health with a Market Perform rating.
01/23/19
UBSW
01/23/19
INITIATION
Target $29
UBSW
Sell
Elanco initiated with a Sell at UBS
UBS analyst Navin Jacob started Elanco Animal Health with a Sell rating and $29 price target. The company has solid fundamentals, but the stock price and long-term consensus estimates are "too far ahead" of what survey work suggests, Jacob tells investors in a research note.
01/15/19
01/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. StoneCo (STNE) initiated with a Buy at BofA/Merrill. 2. Southwest Gas (SWX) initiated with a Market Perform at Wells Fargo. 3. Luna Innovations (LUNA) initiated with a Buy at B. Riley FBR. 4. Dell Technologies (DELL) initiated with a Neutral at UBS. 5. Elanco (ELAN) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/19
02/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Viavi (VIAV) initiated with an Outperform at Northland. 2. CECO Environmental (CECE) initiated with a Buy at B. Riley FBR. 3. Tencent Music (TME) initiated with an Outperform at Macquarie. 4. Enable Midstream (ENBL) initiated with a Neutral at Mizuho. 5. Elanco (ELAN) initiated with a Market Perform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
FCX Freeport McMoRan
$13.09

(0.00%)

02/13/19
02/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Piyush Sood saying his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2, given falling global production, low visible inventories and improved demand from China and Freeport's earnings sensitivity to copper is still the highest among its peers. 2. DocuSign (DOCU) upgraded to Buy from Hold at Deutsche Bank with analyst Karl Keirstead saying that after speaking with four large e-signature customers, three using DocuSign and one using Adobe Sign, the analyst believes a "more constructive call on DocuSign shares is now warranted." 3. Bloom Energy (BE) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying shares are down about 36% since the IPO in July 2018, including a 24% drop since mid-January, the latter due in large part to selling pressure following lockup expiration. 4. Shopify (SHOP) upgraded to Outperform from Sector Perform at RBC Capital with analyst Ross MacMillan saying he anticipates the company to return to new merchant growth this year given its international opportunity and easier comps. 5. Myovant Sciences (MYOV) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying his firm's women's health survey suggests a "robust potential market" for new treatment options for endometriosis and uterine fibroids. The analyst also raised his price target for the shares to $25 from $22. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/19
02/13/19
UPGRADE
Target $14

Overweight
Morgan Stanley bullish on copper, upgrades Freeport McMoRan to Overweight
As previously reported, Morgan Stanley analyst Piyush Sood upgraded Freeport McMoRan to Overweight from Equal Weight, noting that his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2, given falling global production, low visible inventories and improved demand from China. Freeport's earnings sensitivity to copper is still the highest among its peers, said Sood, who sees the stock emerging as "the go-to large-cap stock for exposure to a copper price rally." Concerns about Freeport's ability to ramp production from 2019-21 are overblown, added the analyst, who lowered his price target on the shares to $14 from $16, citing a lower multiple to reflect the overall compression in multiples across equities and management's newly disclosed expectations around costs.
02/19/19
02/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Overweight from Equal Weight at Stephens with analyst Will Slabaugh saying McDonald's core U.S. business is accelerating and positioned to show upside to consensus estimates for Q1 and fiscal 2019. 2. PG&E (PCG) upgraded to Buy from Neutral at Citi with analyst Praful Mehta saying recent comments by California Governor Gavin Newsom indicate an "increasingly likelihood of legislative action." 3. PepsiCo (PEP) upgraded to Outperform from Neutral at Macquarie with analyst Caroline Levy saying new CEO Ramon Laguarta "moved decisively" to reset for sustained 4%-6% sales growth by stepping up marketing and capital spending. 4. Freeport McMoRan (FCX) upgraded to Buy from Neutral at Citi while Southern Copper (SCCO) was double upgraded to Buy from Sell. 5. Cosan (CZZ) upgraded to Overweight from Neutral at JPMorgan with analyst Lucas Ferreira saying the shares trade at an "excessive" 40% discount to net asset value, in the upper part of the 30%-40% range where the stock should be trading. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/19/19
SBSH
02/19/19
UPGRADE
Target $16
SBSH
Buy
Freeport McMoRan upgraded to Buy from Neutral at Citi
Citi analyst Alexander Hacking upgraded Freeport McMoRan (FCX) to Buy with a $16 price target. The analyst cites his firm's more constructive cooper market backdrop for the upgrade. Citi's global commodity team is bullish on copper, noting that exchange inventory is at 10 year lows and Chinese weakness appears to be turning, Hacking tells investors in a research note. The analyst believes copper equities have "significant rebound potential" with the stocks down 30%-40% year-to-date. Hacking this morning also double upgraded Southern Copper (SCCO) to Buy from Sell.
BHC Bausch Health
$25.17

(0.00%)

01/02/19
PIPR
01/02/19
NO CHANGE
PIPR
Piper calls Horizon top 2019 growth idea in Specialty Pharmaceuticals
Piper Jaffray analyst David Amsellem calls Horizon Pharma (HZNP) his top "growth oriented/GARP idea" for 2019. The company offers high asset quality, visibility into significant longer-term EBITDA growth, and manageable debt levels that enable significant business development flexibility, Amsellem tells investors in a research note. He believes the Specialty Pharmaceuticals group is well positioned to perform more in-line with the broader therapeutics and overall healthcare spaces in 2019, or "certainly better than what we have seen in recent years." The analyst names Bausch Health (BHC), a stock he upgraded this morning to Overweight, his top "de-leveraging/defensive pick" for 2019. Further, Amsellem's top "development-stage picks" for 2019 are Cara Therapeutics (CARA) and Revance Therapeutics (RVNC).
01/02/19
01/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bausch Health (BHC) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying while he's been "unrelentingly negative" on the company for years, it is time to "turn the page following a closer look at the business." 2. Crocs (CROX) and Shoe Carnival (SCVL) were upgraded to Positive from Neutral at Susquehanna. 3. Stryker (SYK) upgraded to Outperform from In Line at Evercore ISI. 4. CBS (CBS) upgraded to Overweight from Equal Weight at Stephens with analyst Kyle Evans saying he believes investor sentiment is poised to improve on the name in 2019 and that the company can continue to post solid results driven by underlying unit growth and stronger pricing. 5. Sirius XM (SIRI) upgraded to Overweight from Neutral at JPMorgan with analyst Sebastiano Petti saying Sirius XM shares are attractively following the 25% pullback from the 2018 highs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
PIPR
01/10/19
NO CHANGE
Target $27
PIPR
Overweight
Piper sees Bausch Health as 'stand out' after management meeting
Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Bausch Health Companies with a $27 price target after meeting with management. The analyst says commentary from the company reinforced his view that Bausch will continue to "stand out among the broader group of highly-levered specialty pharma names." Management has high visibility into not only longer-term EBITDA stability but meaningful long-term growth, Amsellem tells investors in a research note. Significant growth from the gastroenterology franchise along with modest growth from the dermatology and eye care segments should translate into a long-term annual EBITDA growth at least in the mid-single digits, says the analyst.
02/19/19
WELS
02/19/19
NO CHANGE
Target $9
WELS
Underperform
Wells says Bausch not pivoting despite new slogan, keeps $9 price target
"Pivoting to Offense" is the new slogan Bausch Health unveiled for investors at the start of the year at an investment conference, Wells Fargo analyst David Maris tells investors in a research note. However, after listening to the presentation and reviewing the slides, the analyst believes that Bausch is not pivoting. The company's message seems similar to the previous Valeant - it remains committed to broad price increases and acquiring products to sell, writes Maris. He points out that the company announced in mid-January a number of price increases in the 6%-8% range on several of its key products, including Vyzulta, Xifaxan, Relistor, Wellbutrin, Apriso, and Lotemax. Further, Salix, without price actions, would not have grown in Q3 of 2018, adds Maris. He thinks investors should ask what percent of growth in Bausch's individual key franchises are reflective of price increases. Maris keeps an Underperform rating on Bausch Health with a $9 price target. The stock closed Tuesday down 26c to $25.19.
WMT Walmart
$102.23

(0.00%)

02/20/19
JEFF
02/20/19
NO CHANGE
Target $115
JEFF
Buy
Walmart target raised to $115 after 'strong' Q4 at Jefferies
Jefferies analyst Christopher Mandeville raised his price target for Walmart to $115 from $112 saying the company's Q4 results were "strong" owing to a "solid" holiday and continued market share gains on "sound" execution. The analyst sees little reason for Walmart's comps to slow and keeps a Buy rating on the shares.
02/20/19
MSCO
02/20/19
NO CHANGE
Target $113
MSCO
Overweight
Walmart Q4 results show top-line strategy working, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said Walmart's Q4 results show the company's top-line strategy is working while Walmart is "distancing itself from the rest of retail." The company's reaffirmed 2019 outlook plus expense leverage is evidence of an impending inflection from profitless to profitable growth, added Gutman, who raised his price target on Walmart shares to $113 from $110 and keeps an Overweight rating on the stock.
02/20/19
FBCO
02/20/19
NO CHANGE
Target $103
FBCO
Neutral
Walmart's productivity loop working, says Credit Suisse
Credit Suisse analyst Seth Sigman notes that Walmart's Q4 results were "strong" and provided further evidence that its efforts to enhance the store experience as well investments in omni-channel are driving stronger market share gains. The analyst expects that comps momentum will continue to dictate the near-term direction of the stock. That said, upside to EBIT still seems limited by those investments, he contends, adding that he would continue to look for progress toward enhancing the sales mix and executing on other cost offsets to support stronger profitability, in order to drive more meaningful upside to the stock over the medium/longer term. Sigman reiterates a Neutral rating and $103 price target on the shares.
02/20/19
WELS
02/20/19
NO CHANGE
Target $98
WELS
Market Perform
Walmart's Q4 a 'solid end' to encouraging year, says Wells Fargo
Wells Fargo analyst Edward Kelly notes that Walmart provided a "reasonably solid" Q4, as the company beat on top-line strength and maintained its outlook for 2019. Overall, the analyst believes the quarter was very much in line with the company's long-term strategy and outlook, but the stock looks fairly valued given its limited growth and the lack of visibility on this changing anytime soon. He reiterates a Market Perform rating and a $98 price target on the shares.
ADBE Adobe
$257.84

(0.00%)

01/16/19
SPHN
01/16/19
INITIATION
Target $278
SPHN
Equal Weight
Adobe initiated with an Equal Weight at Stephens
Stephens analyst James Rutherford started Adobe with an Equal Weight rating and $278 price target, stating that he sees the company being set up to "achieve years of profitable growth," given its "de facto ownership" of the creative software market and dominant position in the digital experience market, but he would recommend waiting for a better entry point given the stock's valuation.
01/17/19
01/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tencent Music (TME) initiated with an Overweight at JPMorgan. 2. Craft Brew (BREW) initiated with a Buy at Maxim while Castle Brands (ROX) was initiated with a Hold. 3. CVS Health (CVS) and LabCorp (LH) were initiated with a Buy at UBS while Walgreens Boots Alliance (WBA) was initiated with a Sell. 4. DTE Energy (DTE) initiated with a Buy at Goldman Sachs while CMS Energy (CMS) was initiated with a Neutral. 5. Zendesk (ZEN) and HubSpot (HUBS) were initiated with an Overweight at Stephens while Adobe (ADBE) was initiated with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/15/19
COWN
02/15/19
DOWNGRADE
COWN
Market Perform
Adobe downgraded to Market Perform from Outperform at Cowen
02/06/19
BMOC
02/06/19
NO CHANGE
Target $145
BMOC
Market Perform
Tableau price target raised to $145 from $125 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Tableau (DATA) to $145 after its 2019 annual recurring revenue growth outlook of mid-30%. The analyst notes that while the management affirmed its FY19 revenue view, the ARR outlook should support investor interest. Bachman is also keeping his Market Perform rating on Tableau, stating that Adobe (ADBE) and salesforce (CRM) are his preferred companies in the space given their growth profiles.
F Ford
$8.83

(0.00%)

02/13/19
GHSC
02/13/19
INITIATION
GHSC
Neutral
Ford initiated with a Neutral on valuation at Seaport Global
Seaport Global analyst Michael Ward initiated Ford with a Neutral citing valuation and said the company's current financial position will make it difficult to get concessions and keep shares range bound.
01/23/19
MSCO
01/23/19
NO CHANGE
Target $10
MSCO
Equal Weight
Ford EPS to fall to under 60c from 2020-2022, says Morgan Stanley
Morgan Stanley analyst Adam Jonas "tweaked" his 2019 EPS estimate for Ford to 85c from 83c after the Detroit auto show and the company's report of preliminary 2018 results, noting that he forecasts 2019 revenues to be down 2.4%, primarily due to expectations for a loss of global market share and a 4% decline in volume. However, Jonas added that he sees earnings falling further, to under 60c per share, from 2020 through 2022, noting that his EPS estimates are about one-third below consensus. He expects Ford's dividend to be unchanged for the current quarter, but expects a 50% dividend cut from the second quarter of 2019 on, Jonas added. He maintains an Equal Weight rating and $10 price target on Ford shares ahead of the company's report of Q4 results after today's close.
02/13/19
GHSC
02/13/19
INITIATION
GHSC
Neutral
Ford initiated with a Neutral at Seaport Global
02/20/19
MSCO
02/20/19
NO CHANGE
Target $10
MSCO
Equal Weight
Morgan Stanley would fade Ford rally on SA heavy truck exit news
After Ford announced yesterday that it will exit the commercial heavy truck business in South America and expects to record pre-tax special item charges of about $460M as a result, Morgan Stanley analyst Adam Jonas said he would fade the rally following the news given that he sees the situation as "highly volatile." Ford's restructuring efforts help address its negatively valued business in South America, but some investors may have hoped for more significant actions, added Jonas, who keeps an Equal Weight rating on Ford with a $10 price target.

TODAY'S FREE FLY STORIES

01:50
09/19/19
09/19
01:50
09/19/19
01:50
General news
Asian Market Wrap »

Asian Market Wrap: Asian…

01:40
09/19/19
09/19
01:40
09/19/19
01:40
General news
Norges Bank decision could go either way. »

Norges Bank decision…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. initial claims preview »

U.S. initial claims…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. Philly Fed preview »

U.S. Philly Fed preview:…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. existing home sales preview »

U.S. existing home sales…

01:15
09/19/19
09/19
01:15
09/19/19
01:15
General news
BoJ left policy on hold »

BoJ left policy on hold…

AKAM

Akamai

$90.95

-0.13 (-0.14%)

21:13
09/18/19
09/18
21:13
09/18/19
21:13
Downgrade
Akamai rating change at KeyBanc »

Akamai downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

DB

Deutsche Bank

$8.06

-0.125 (-1.53%)

20:32
09/18/19
09/18
20:32
09/18/19
20:32
Hot Stocks
Deutsche Bank lowers prime lending rate to 5.00% from 5.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRVB

Provention Bio

$9.70

0.33 (3.52%)

20:31
09/18/19
09/18
20:31
09/18/19
20:31
Syndicate
Provention Bio 5M share Spot Secondary priced at $8.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 19

    Sep

DRI

Darden

$127.40

1.31 (1.04%)

20:25
09/18/19
09/18
20:25
09/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

19:48
09/18/19
09/18
19:48
09/18/19
19:48
Syndicate
Exagen 3.6M share IPO priced at $14.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PING

Ping Identity

$0.00

(0.00%)

19:35
09/18/19
09/18
19:35
09/18/19
19:35
Syndicate
Ping Identity 12.5M share IPO priced at $15.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CBS

CBS

$43.38

0.08 (0.18%)

, T

AT&T

$36.77

-0.39 (-1.05%)

19:04
09/18/19
09/18
19:04
09/18/19
19:04
Periodicals
Viacom, CBS, WarnerMedia pull e-cigarette ads from networks, CNBC says »

CBS (CBS),…

CBS

CBS

$43.38

0.08 (0.18%)

T

AT&T

$36.77

-0.39 (-1.05%)

VIA

Viacom

$27.94

-0.06 (-0.21%)

VIAB

Viacom

$25.77

0.02 (0.08%)

BTI

British American Tobacco

$36.90

0.06 (0.16%)

MO

Altria Group

$40.84

-0.47 (-1.14%)

PM

Philip Morris

$71.58

-0.4 (-0.56%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

CRON

Cronos Group

$10.96

-0.205 (-1.84%)

18:57
09/18/19
09/18
18:57
09/18/19
18:57
Hot Stocks
Cronos Group CEO: We focus on supply and the consumer »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

, SVRA

Savara

$2.49

-0.14 (-5.32%)

18:46
09/18/19
09/18
18:46
09/18/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

SVRA

Savara

$2.49

-0.14 (-5.32%)

CBPO

China Biologic

$103.19

0.37 (0.36%)

NCR

NCR Corp.

$33.62

0.77 (2.34%)

MSFT

Microsoft

$138.53

1.13 (0.82%)

TNDM

TNDM

X

U.S. Steel

$12.45

-0.51 (-3.94%)

PRVB

Provention Bio

$9.70

0.33 (3.52%)

PAA

Plains All American

$21.87

-0.315 (-1.42%)

COST

Costco

$292.47

0.96 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 21

    Oct

  • 22

    Oct

  • 27

    Oct

  • 05

    Nov

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

TECD

Tech Data

$103.32

-0.59 (-0.57%)

18:41
09/18/19
09/18
18:41
09/18/19
18:41
Hot Stocks
Tech Data CEO: We are confident in our company and where we are going »

Tech Data CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

18:34
09/18/19
09/18
18:34
09/18/19
18:34
Periodicals
AT&T, Dish not in discussions over DirecTV deal, Reuters reports »

AT&T (T) and Dish…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

AGCO

Agco

$76.04

-0.16 (-0.21%)

18:30
09/18/19
09/18
18:30
09/18/19
18:30
Hot Stocks
Agco CEO: We are on schedule in the U.S. »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.63

-0.31 (-2.08%)

18:22
09/18/19
09/18
18:22
09/18/19
18:22
Periodicals
Petrobras raises gasoline, diesel prices in wake of Saudi attacks, Reuters says »

Petrobras has boosted the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$123.69

-0.28 (-0.23%)

18:01
09/18/19
09/18
18:01
09/18/19
18:01
Hot Stocks
Celanese increases Vinyl Acetate Monomer price in EMEA by EUR50/MT »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STI

SunTrust

$68.57

0.48 (0.70%)

18:00
09/18/19
09/18
18:00
09/18/19
18:00
Hot Stocks
SunTrust lowers prime lending rate to 5% from 5.25% »

Following the Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBS

Webster Financial

$48.84

0.43 (0.89%)

17:53
09/18/19
09/18
17:53
09/18/19
17:53
Hot Stocks
Webster Financial lowers prime lending rate to 5.0% from 5.25% 

Effective September 19.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 13

    Nov

HSBC

HSBC

$38.19

-0.1 (-0.26%)

17:52
09/18/19
09/18
17:52
09/18/19
17:52
Hot Stocks
HSBC decreases prime lending rate to 5% from 5.25% »

HSBC Bank USA and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

HES

Hess Corp.

$66.91

-0.92 (-1.36%)

17:50
09/18/19
09/18
17:50
09/18/19
17:50
Hot Stocks
Hess Corp. COO sells 17,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

CSCO

Cisco

$49.32

-0.1 (-0.20%)

, DDOG

Datadog

$0.00

(0.00%)

17:46
09/18/19
09/18
17:46
09/18/19
17:46
Periodicals
Cisco approached Datadog with $7B+ takeover bid, Bloomberg says »

Cisco (CSCO) approached…

CSCO

Cisco

$49.32

-0.1 (-0.20%)

DDOG

Datadog

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.